+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
POLYMED

Poly Medicure Share Price

 

 

Poly Medicure live price: ₹1458.8. It opened at ₹1,390 vs previous close ₹1,383; intraday high/low: ₹1,467/₹1,390. The 50 & 200 DMA stand at ₹1,454.42/₹1,653.78.

Poly Medicure Performance

  • Today's Low
  • ₹1,390
  • Today's High
  • ₹1,467
  • 52 Week Low
  • ₹1,182
  • 52 Week High
  • ₹2,317
  • Open Price₹1,390
  • Previous Close₹1,383
  • Volume300,893
  • 50 DMA₹1,454.42
  • 100 DMA₹1,505.61
  • 200 DMA₹1,653.78

Poly Medicure Chart

Investment Returns

  • Over 1 Month -11.7%
  • Over 3 Month + 7.57%
  • Over 6 Month -21.49%
  • Over 1 Year -34.67%

Smart Investing Starts Here Start SIP with Poly Medicure for Steady Growth!

Invest Now

Poly Medicure Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 45.9
  • PEG Ratio
  • -9.5
  • Market Cap Cr
  • 14,786
  • P/B Ratio
  • 4.9
  • Average True Range
  • 68.54
  • EPS
  • 32.29
  • Dividend Yield
  • 0.2
  • MACD Signal
  • -22.22
  • RSI
  • 43.77
  • MFI
  • 36.74

Latest Stock News Updates

Q4FY26 & FY26 Result Announced for Poly Medicure Ltd.

Healthcare Supplies company Poly Medicure announced Q4FY26 & FY26 results Consolidated Financial Highlights: Revenue from Operations: For Q4FY26, Revenue from Operations stood at Rs 53,451.14 lakh, registering a growth of 8.28% QoQ compared to Rs 49,365.55 lakh in Q3FY26, and a strong increase of 21.25% YoY from Rs 44,082.82 lakh in Q4FY25. Annual Revenue from Operations: For the full year FY26, Revenue from Operations amounted to Rs 1,87,525.92 lakh, reflecting a 12.30% YoY growth from Rs 1,66,983.16 lakh in FY25. Total Income: In Q4FY26, Total Income reached Rs 55,226.79 lakh, up by 6.22% QoQ from Rs 51,991.89 lakh in Q3FY26, and higher by 18.73% YoY compared to Rs 46,513.77 lakh in Q4FY25. Annual Total Income: For FY26, Total Income stood at Rs 1,99,534.14 lakh, an increase of 13.44% YoY against Rs 1,75,895.92 lakh in FY25. Net Profit: Net Profit for Q4FY26 was reported at Rs 6,504.10 lakh, reflecting a decline of 8.15% QoQ from Rs 7,080.89 lakh in Q3FY26, and a decrease of 29.18% YoY from Rs 9,183.42 lakh in Q4FY25. Annual Net Profit: For FY26, Net Profit stood at Rs 32,072.99 lakh, a slight drop of 5.27% YoY compared to Rs 33,855.72 lakh in FY25. Total Comprehensive Income: Total Comprehensive Income for Q4FY26 was Rs 8,993.90 lakh, and for the full year FY26, it amounted to Rs 36,721.58 lakh. Standalone Financial Highlights: Revenue from Operations: Revenue from Operations for Q4FY26 came in at Rs 44,301.49 lakh, up by 5.77% QoQ from Rs 41,886.15 lakh in Q3FY26, and growing by 5.24% YoY from Rs 42,096.94 lakh in Q4FY25. Annual Revenue from Operations: For FY26, Annual Revenue from Operations was Rs 1,66,246.48 lakh, showing an increase of 3.79% YoY against Rs 1,60,179.98 lakh in FY25. Total Income: Total Income for Q4FY26 was Rs 45,813.68 lakh, registering an increase of 2.17% QoQ against Rs 44,841.37 lakh in Q3FY26, and a 2.97% growth YoY from Rs 44,491.80 lakh in Q4FY25. Annual Total Income: For FY26, Annual Total Income stood at Rs 1,78,238.25 lakh, growing 5.37% YoY from Rs 1,69,157.22 lakh in FY25. Net Profit: Net Profit for Q4FY26 was Rs 8,062.17 lakh, increasing by 2.86% QoQ from Rs 7,838.38 lakh in Q3FY26, but declining by 6.97% YoY from Rs 8,666.02 lakh in Q4FY25. Annual Net Profit: For FY26, Net Profit was Rs 33,598.49 lakh, reflecting a marginal growth of 1.40% YoY from Rs 33,133.47 lakh in FY25. Total Comprehensive Income: Total Comprehensive Income for Q4FY26 was Rs 8,125.00 lakh, and for the full year FY26, it stood at Rs 33,621.11 lakh. Business & Segment Highlights: Dividend: The Board of Directors recommended a dividend of Rs 3.50 (70%) per Equity Share of Rs 5 each for the financial year 2025-26, subject to the approval of shareholders. Segment Performance: The company's operations fall entirely under "Medical Devices", which is considered to be the only reportable segment by the management. Therefore, overall financial results fully reflect the performance of this single segment. Fund Raising (QIP): The company successfully raised Rs 99,999.98 lakh during the previous year by issuing 53,19,148 equity shares of Rs 5 each at a premium of Rs 1,875 each (issue price of Rs 1,880 per share) to Qualified Institutional Investors on a QIP basis. Strategic Acquisitions: The Group acquired 90% economic rights in the Pendracare Group (comprising Pendracare Holdings BV and Welling Medical BV) through RISOR Holding BV. The Group also acquired 100% economic rights in Medistream SA, Switzerland (comprising Citieffe group) through its wholly owned subsidiary company Poly Medicure BV Netherlands. Resolution Plan Approval: The Hon’ble NCLT of Allahabad approved the company's resolution plan for Himalayan Mineral Water Private Limited (Target Company). An amount of Rs 3,316.00 lakh has been deposited to acquire 100% equity shareholding in the target company. Auditor Appointments: The company approved the re-appointment of M/s. PricewaterhouseCoopers Services LLP and M/s Oswal Sunil & Co. (Chartered Accountants) as Internal Auditors for FY27. Result PDF

Q3FY26 Quarterly Result Announced for Poly Medicure Ltd.

Healthcare Supplies company Poly Medicure announced Q3FY26 results Revenue: Rs 493.7 crore against Rs 424.2 crore during Q3FY25, change 16%. EBITDA: Rs 119.4 crore against Rs 116.1 crore during Q3FY25, change 3%. EBITDA Margin: 24.2% for Q3FY26. PBT: Rs 97.6 crore against Rs 113.2 crore during Q3FY25, change -14%. PAT: Rs 70.8 crore against Rs 85.2 crore during Q3FY25, change -17%. PAT Margin: 13.6% for Q3FY26. EPS: Rs 7 for Q3FY26. Result PDF

Poly Medicure Results Earnings Call for Q2FY26

Conference Call with Poly Medicure Management and Analysts on Q2FY26 Performance and Outlook. Listen to the full earnings transcript.

Poly Medicure Financials

Poly Medicure Technicals

EMA & SMA

Current Price
₹1,458.80
+ 76 (5.5%)
pointer
  • Bearish Moving Average 6
  • Bullish Moving Average 10
  • 20 Day
  • ₹1,436.44
  • 50 Day
  • ₹1,454.42
  • 100 Day
  • ₹1,505.61
  • 200 Day
  • ₹1,653.78

Resistance and Support

1394.87 Pivot Speed
  • R3 1,479.43
  • R2 1,455.27
  • R1 1,419.03
  • S1 1,358.63
  • S2 1,334.47
  • S3 1,298.23

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Poly Medicure Ltd. is a leading Indian manufacturer of medical devices, specializing in infusion therapy, dialysis, urology, and diagnostics. With 8 global manufacturing facilities, it delivers high-quality healthcare products to patients and healthcare providers worldwide.

Poly Medicure has an operating revenue of Rs. 1,875.26 Cr. on a trailing 12-month basis. An annual revenue growth of 13% is good, Pre-tax margin of 22% is great, ROE of 10% is good. The company has a reasonable debt to equity of 2%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 55 which is a POOR score indicating inconsistency in earnings, a RS Rating of 22 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 151 indicates it belongs to a poor industry group of Medical-Systems/Equip and a Master Score of D is close to being the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Poly Medicure Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-05-25 Audited Results & Final Dividend
2026-02-05 Quarterly Results
2025-11-08 Quarterly Results
2025-08-08 Quarterly Results & Others To consider other business matters. per share(50%)Dividend
2025-05-06 Audited Results & Final Dividend
Date Purpose Remarks
2025-09-18 FINAL Rs.3.50 per share(70%)Final Dividend
View Poly Medicure Dividend History Arrow

Poly Medicure Shareholding Pattern

62.42%
8.84%
3.34%
5.92%
12.6%
6.88%

Poly Medicure FAQs

Poly Medicure share price is ₹1,458 As on 09 June, 2026 | 16:24

The Market Cap of Poly Medicure is ₹14786.3 Cr As on 09 June, 2026 | 16:24

The P/E ratio of Poly Medicure is 45.9 As on 09 June, 2026 | 16:24

The PB ratio of Poly Medicure is 4.9 As on 09 June, 2026 | 16:24

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23